These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30323863)

  • 1. Clinical efficacy of sublingual immunotherapy is associated with restoration of steady-state serum lipocalin 2 after SLIT: a pilot study.
    Roth-Walter F; Schmutz R; Mothes-Luksch N; Lemell P; Zieglmayer P; Zieglmayer R; Jensen-Jarolim E
    World Allergy Organ J; 2018; 11(1):21. PubMed ID: 30323863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
    Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
    Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
    JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial.
    Zieglmayer P; Nolte H; Nelson HS; Bernstein DI; Kaur A; Jacobi H; Lemell P; Schmutz R; Zieglmayer R; Horak F
    Ann Allergy Asthma Immunol; 2016 Dec; 117(6):690-696.e1. PubMed ID: 27979028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses.
    Durham SR; Creticos PS; Nelson HS; Li Z; Kaur A; Meltzer EO; Nolte H
    J Allergy Clin Immunol; 2016 Oct; 138(4):1081-1088.e4. PubMed ID: 27527264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
    Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
    J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
    Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
    J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of house dust mite sublingual immunotherapy on the TSLP-OX40L signaling pathway in patients with allergic rhinitis.
    Meng Q; Liu X; Li P; He L; Xie J; Gao X; Wu X; Su F; Liang Y
    Int Forum Allergy Rhinol; 2016 Aug; 6(8):862-70. PubMed ID: 27012942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between biomarkers and house dust mite sublingual immunotherapy in allergic asthma.
    Hoshino M; Akitsu K; Kubota K; Ohtawa J
    Clin Exp Allergy; 2020 Sep; 50(9):1035-1043. PubMed ID: 32557974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
    J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allergen Immunotherapy Enhances Airway Epithelial Antiviral Immunity in Patients with Allergic Asthma (VITAL Study): A Double-Blind Randomized Controlled Trial.
    Woehlk C; Ramu S; Sverrild A; Nieto-Fontarigo JJ; Vázquez-Mera S; Cerps S; Pulga A; Andreasson LM; Eriksen LL; Dyhre-Petersen N; Menzel M; Klein DK; Hansen S; Uller L; Porsbjerg C
    Am J Respir Crit Care Med; 2023 May; 207(9):1161-1170. PubMed ID: 36701676
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum Soluble ST2 Correlated with Symptom Severity and Clinical Response of Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis Patients.
    Zhu K; Xia C; Chen J; Yu C; Gao T; Yan J; Shao N; Zhu P; Sun B; Ren X; Zhang Y
    Mediators Inflamm; 2021; 2021():5576596. PubMed ID: 34194284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
    Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
    J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New perspectives in allergen specific immunotherapy driven by big trials with house dust mite sublingual SQ
    Vitiello G; Maltagliati L; Rossi O
    Clin Mol Allergy; 2020; 18():10. PubMed ID: 32536827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis.
    Bozek A; Ignasiak B; Filipowska B; Jarzab J
    Clin Exp Allergy; 2013 Feb; 43(2):242-8. PubMed ID: 23331565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.
    Maloney J; Prenner BM; Bernstein DI; Lu S; Gawchik S; Berman G; Kaur A; Li Z; Nolte H
    Ann Allergy Asthma Immunol; 2016 Jan; 116(1):59-65. PubMed ID: 26553448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of silver birch and house dust mite extracts derived from licensed sublingual tablets for nasal allergen challenge.
    Olivieri B; Gil AJ; Stoenchev K; Durham SR; Scadding G
    Clin Transl Allergy; 2024 May; 14(5):e12360. PubMed ID: 38779783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases.
    Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW
    Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.